Seely Lynn (CIK 1327111) reported 14 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-08-11). Recent activity: Sell LYEL (390 shares), Sell LYEL (388 shares), Sell LYEL (7,455 shares), Buy LYEL (20,000 shares), Sell LYEL (438 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 390 | $5,593 |
| 2026-06-15 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 388 | $7,337 |
| 2026-02-12 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 7,455 | $174,372 |
| 2026-02-11 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Buy | 20,000 | $0 |
| 2026-02-11 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 438 | $10,127 |
| 2025-11-12 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 412 | $6,637 |
| 2025-08-22 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Buy | 40,000 | $0 |
| 2025-08-22 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 7,257 | $76,489 |
| 2025-08-13 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 391 | $4,117 |
| 2025-08-13 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Sell | 406 | $4,198 |
| 2025-07-21 | Blueprint Medicines Corp (BPMC) | Director | Sell | 3,902 | $0 |
| 2025-07-21 | Blueprint Medicines Corp (BPMC) | Director | Sell | 13,254 | $0 |
| 2025-06-24 | Blueprint Medicines Corp (BPMC) | Director | Buy | 3,902 | $499,924 |
| 2025-03-18 | Lyell Immunopharma, Inc. (LYEL) | President and CEO | Buy | 175,000 | $106,750 |
Source: SEC Form 4 filings · as of 2026-08-11